Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

Purpose: p21-activated kinase 4 (PAK4) plays a significant biological and functional role in a number of malignancies, including multiple myeloma (MM). On the basis of our promising findings in MM, we here characterize PAK4 expression and role in WM cells, as well effect of dual PAK4-NAMPT inhibitor (KPT-9274) against WM cell growth and viability. Experimental Design: We have analyzed mRNA and protein expression levels of PAK4 in WM cells, and used loss-of-function approach to investigate its contribution to WM cell viability. We have further tested the in vitro and in vivo effect of KPT-9274 against WM cell growth and viability. Results: We report here high-level expression and functional role of PAK4 in WM, as demonstrated by shRNA-mediated knockdown; and significant impact of KPT-9274 on WM cell growth and viability. The growth inhibitory effect of KPT-9274 was associated with decreased PAK4 expression and NAMPT activity, as well as induction of apoptosis. Interestingly, in WM cell lines treated with KPT-9274, we detected a significant impact on DNA damage and repair genes. Moreover, we observed that apart from inducing DNA damage, KPT-9274 specifically decreased RAD51 and the double-strand break repair by the homologous recombination pathway. As a result, when combined with a DNA alkylating agents bendamustine and melphalan, KPT-9274 provided a synergistic inhibition of cell viability in WM cell lines and primary patient WM cells in vitro and in vivo. Conclusions: These results support the clinical investigation of KPT-9274 in combination with DNA-damaging agent for treatment of WM.

[1]  C. Heske.  Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy , 2020, Frontiers in Oncology.

[2]  A. Azmi,et al.  PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors , 2019, Cancers.

[3]  E. Baloglu,et al.  Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia , 2018, Leukemia.

[4]  A. Azmi,et al.  Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation , 2019, Small GTPases.

[5]  Zhi Wei,et al.  PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas , 2017, Nature.

[6]  N. Munshi,et al.  Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. , 2017, Blood.

[7]  E. Baloglu,et al.  A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth , 2017, Scientific Reports.

[8]  S. Treon,et al.  Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Azmi,et al.  Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma , 2016, Molecular Cancer Therapeutics.

[10]  S. Treon,et al.  Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. , 2016, Blood.

[11]  E. Baloglu,et al.  Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth , 2016, Molecular Cancer Therapeutics.

[12]  N. Munshi,et al.  Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status , 2016, Clinical Cancer Research.

[13]  S. Anand,et al.  Kinase-independent role for CRAF-driving tumour radioresistance via CHK2 , 2015, Nature Communications.

[14]  G. Gaidano,et al.  Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia , 2014, Leukemia & lymphoma.

[15]  E. Wagner,et al.  Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. , 2014, Cancer cell.

[16]  R. Sobol,et al.  ARTD1 (PARP1) activation and NAD(+) in DNA repair and cell death. , 2014, DNA repair.

[17]  R. Advani,et al.  Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. , 2014, Blood.

[18]  S. Treon,et al.  The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. , 2014, Blood.

[19]  J. Chernoff,et al.  PAK signalling during the development and progression of cancer , 2013, Nature Reviews Cancer.

[20]  N. Gray,et al.  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. , 2013, Blood.

[21]  Da-Qiang Li,et al.  Identification of Novel Gene Targets and Functions of p21-Activated Kinase 1 during DNA Damage by Gene Expression Profiling , 2013, PloS one.

[22]  L. Aravind,et al.  MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response. , 2012, Cell reports.

[23]  N. Munshi,et al.  Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. , 2012, Blood.

[24]  M. Ziegler,et al.  The NAD metabolome — a key determinant of cancer cell biology , 2012, Nature Reviews Cancer.

[25]  Peter Bouwman,et al.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.

[26]  S. Diamond,et al.  Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. , 2011, ACS chemical biology.

[27]  S. Treon,et al.  Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. , 2011, Clinical lymphoma, myeloma & leukemia.

[28]  W. Dalton,et al.  Experimental Therapeutics , Molecular Targets , and Chemical Biology Targeting the Fanconi Anemia / BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma , 2009 .

[29]  S. Treon.  How I treat Waldenström macroglobulinemia. , 2009, Blood.

[30]  Bruce D Cheson,et al.  Bendamustine: rebirth of an old drug. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. Munshi,et al.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. , 2007, Blood.

[32]  K. Vousden,et al.  Coping with stress: multiple ways to activate p53 , 2007, Oncogene.

[33]  V. Yamazaki,et al.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage , 2000, Current Biology.

[34]  A. Abo,et al.  PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia , 1998, The EMBO journal.

[35]  C. Norbury,et al.  Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. , 1995, Trends in biochemical sciences.

[36]  K. Kohn,et al.  p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. , 1994, Cancer research.